Patents Examined by Yong Chu
  • Patent number: 8278084
    Abstract: Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: October 2, 2012
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • Patent number: 8278364
    Abstract: The invention concerns a method for optimizing the operation of a reaction section for hydrocarbon synthesis starting from a feed comprising synthesis gas, operated in the presence of a catalyst comprising cobalt. This method comprises the following steps: a) determining the theoretical molar ratio, PH2O:PH2, in the reaction section; b) optionally, adjusting the ratio PH2O:PH2 determined in step a) to a value strictly below 1; c) determining the new value for the theoretical ratio PH2O:PH2 in the reaction section; and repeating steps a) to c) until the ratio of the partial pressures of water and hydrogen, PH2O:PH2, has a value strictly less than 1.1.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: October 2, 2012
    Assignee: IFP Energies nouvelles
    Inventors: Marie-Claire Marion, Francois Hugues
  • Patent number: 8273776
    Abstract: The present invention relates to novel biphenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc
    Inventors: Janet A. Takeuchi, Ken Chow, Ling Li
  • Patent number: 8273787
    Abstract: Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: September 25, 2012
    Assignee: Onconova Therapeutics, Inc
    Inventors: Stanley C Bell, Glenn Fegley, Stephen Cosenza, Jodie Duke, Reddy E Premkumar, Reddy M. V. Ramana
  • Patent number: 8273896
    Abstract: The present invention relates to processes for the preparation of compounds useful as inhibitors of p38 kinase. The processes of the present invention are amenable for large scale preparation and produce stable phenyl-6-(1-(phenyl)ureido)nicotinamides in high purity and yields.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: September 25, 2012
    Assignee: Vertex Pharmaceutical Incorporated
    Inventors: Stefanie Roeper, Adam R. Looker, Theodore A. Martinot, Bobbianna Neubert-Langille, Michael P. Ryan, John R. Snoonian
  • Patent number: 8273737
    Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: September 25, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Ronald K. Chang
  • Patent number: 8263630
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are defined herein.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventor: James J. Li
  • Patent number: 8263595
    Abstract: The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: September 11, 2012
    Assignee: Merck Serono SA
    Inventors: Dominique Swinnen, Catherine Jorand-Lebrun, Tania Grippi-Vallotton, Mathilde Muzerelle, Amanda Royle, Jacqueline MacRitchie, Richard Hill, Jeffrey P. Shaw
  • Patent number: 8258292
    Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: September 4, 2012
    Assignee: AnaSpec Incorporated
    Inventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
  • Patent number: 8252830
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: August 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Joanne M. Smallheer, James R. Corte, Zilun Hu, Cullen L. Cavallaro, Paul J. Gilligan, Mimi L. Quan, Leon M. Smith, II
  • Patent number: 8252780
    Abstract: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: August 28, 2012
    Assignees: Women & Infants' Hospital, Louisiana State University
    Inventors: Laurent Brard, Rakesh Singh, Satyan Kalkunte, Robert Strongin, Onur Alpturk
  • Patent number: 8247442
    Abstract: The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: August 21, 2012
    Assignee: Purdue Pharma L.P.
    Inventors: Zhengming Chen, Khondaker Islam, Bin Shao, Jiangchao Yao, Donald J. Kyle
  • Patent number: 8247432
    Abstract: The present invention is concerned with novel compounds of formula (I) which are inhibitors of a membrane tripeptidyl peptidase responsible for the inactivation of endogenous neuropeptides such as cholecystokinis (CCKs).
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: August 21, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Henry Joseph Breslin, Hans Louis Jos De Winter, Michael Joseph Kukla
  • Patent number: 8242164
    Abstract: In one aspect, the invention relates to compounds of formula I: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: August 14, 2012
    Assignee: Theravance, Inc.
    Inventors: Eric L. Stangeland, Priscilla Van Dyke, Timothy J. Church, Lori Jean Patterson, Daisuke Roland Saito
  • Patent number: 8242283
    Abstract: A pesticide, particularly an insecticide or an acaricide, including a substituted isoxazoline compound of formula (1) or a salt thereof: wherein A1, A2 and A3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., L is —N(R2c)—, or —CH(R2a)N(R2c)—, etc., X is halogen atom, C1-C6 haloalkyl, etc., Y is halogen atom, C1-C6alkyl, etc., R1 is —C(O)R1a, —C(O)OR1a, —C(O)NHR1a, etc., R2 is hydrogen atom, C1-C6haloalkyl, —C1-C4alkoxy C1-C4alkyl, cyano C1-C6alkyl, C3-C6alkenyl, C3-C6alkynyl, —C(O)R15, —C(O)OR15, etc., R3 is C1-C6haloalkyl, etc., m is an integer of 0 to 5, n is an integer of 0 to 4. The pesticide containing these compounds.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: August 14, 2012
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Takeshi Mita, Kazushige Maeda, Mitsuaki Komoda, Eitatsu Ikeda, Ken-ichi Toyama, Motoyoshi Iwasa
  • Patent number: 8242163
    Abstract: The present invention relates to a method for treating insulin resistance, neuronal loss associated with stroke, ischemia, central nervous system trauma, a central nervous system disorder, a neurodegenerative disease, the adverse consequences of the over-stimulation of excitatory amino acids, a psychiatric disease, epilepsy or other convulsive disorder, chronic pain, CMV retinitis, urinary incontinence, or for inducing anesthesia; which comprises administering to an animal or human in need thereof an effective amount of a pharmaceutical formulation comprising an effective amount of a pyrone-indole derivative of formula (I): Ar—B—Ar???(I) wherein Ar represents an indole nucleus ring system: Ar? represents an alpha-, beta- or gamma-pyrone nucleus ring system: and each of B, R1-4, and R1-2? are one of the groups as defined herein.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: August 14, 2012
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Moshe Laudon, Tal Peleg-Shulman
  • Patent number: 8241822
    Abstract: Compounds of the formula I or II wherein R1 is C1-C10haloalkylsulfonyl, halobenzenesulfonyl, C2-C10haloalkanoyl, halobenzoyl; R2 is halogen or C1-C10haloalkyl; Ar1 is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl, or heteroaryl, all of which are optionally substituted; Ar?1 is for example phenylene, naphthylene, diphenylene, heteroarylene, oxydiphenylene, phenylene-D-D1-D-phenylene or —Ar?1-A1-Y1-A1-Ar?1—; wherein these radicals optionally are substituted; Ar?1 is phenylene, naphthylene, anthracylene, phenanthrylene, or heteroarylene, all optionally substituted; A1 is for example a direct bond, —O—, —S—, or —NR6—; Y1 inter alia is C1-C18alkylene; X is halogen; D is for example —O—, —S— or —NR6—; D1 inter alia is C1-C18alkylene; are particularly suitable as photolatent acids in ArF resist technology.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: August 14, 2012
    Assignee: BASF SE
    Inventors: Hitoshi Yamato, Toshikage Asakura, Akira Matsumoto, Peter Murer, Tobias Hintermann
  • Patent number: 8236846
    Abstract: The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: August 7, 2012
    Assignee: Theravance, Inc.
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson
  • Patent number: 8236829
    Abstract: Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: August 7, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Timothy Donald Neubert, Aarti Sameer Kawatkar, Esther Ann Martinborough, Andreas P. Termin, Nicole Hilgraf
  • Patent number: 8232376
    Abstract: An azo compound having the following formula (I): A(E)n??(I) wherein A represents a residue of an azo compound, bonded with n pieces of E group through one or more heteroatom being N or O and forming a part of the residue A; E independently represents a hydrogen atom or —C(?O)—O—R1 wherein R1 represents a substituted or an unsubstituted alkyl group having 4 to 10 carbon atoms, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group or an aralkyl group; and n represents an integer of from 1 to 10.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: July 31, 2012
    Assignee: Ricoh Company, Ltd.
    Inventor: Masafumi Ohta